In addition, in a subanalysis from the study of Tirzepatide in Participants with Heart Failure with Preserved Ejection fraction and Obesity (SUMMIT) trial, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 agonist tirzepatide mainly reduced extrapericardial adipose tissue, the adipose tissue situated outside the parietal pericardium, which is less likely to cause pericardial constraint, and not EAT itself.33 The gene discussed is GIP; the disease is obesity disorder.